Navigation Links
Arena Pharmaceuticals Announces Third Quarter 2010 Financial Results and Reviews Recent Developments
Date:11/9/2010

and activities thereunder; and Arena's focus, goals, strategy, research and development programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, top-line results are based on a preliminary analysis of then available data, and such findings and conclusions are subject to change following a more comprehensive review of the data; the risk that regulatory authorities may not find data and other information related to Arena's clinical trials and other studies meet safety or efficacy requirements or are otherwise sufficient for regulatory approval; the timing of regulatory review and approval is uncertain; Arena's response to the complete response letter for the lorcaserin NDA may not be submitted in a timely manner and/or the information provided in such response may not satisfy the FDA; the FDA may request additional information prior to approval; unexpected new data; risks related to commercializing new products; Arena's ability to obtain and defend its patents; the timing, success and cost of Arena's research and development programs; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner Arena or others expect or at all; Arena's ability to obtain adequate funds; risks related to relying on collaborative agreements; the timing and receipt of payments and fees, if any, from Arena's collaborators; and satisfactory resolution of pending and any future litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Are
'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Arena Pharmaceuticals Provides Update on GPR119 Portfolio for Type 2 Diabetes
2. Endologix Announces Publication of Clinical Trial Results Supporting Anatomical Fixation with a Suprarenal Aortic Extension
3. Arena and Eisai Announce Upcoming Lorcaserin Presentations at Obesity 2010
4. Arena and Eisai Provide Update on Lorcaserin FDA Advisory Committee Meeting
5. Arena Pharmaceuticals to Host Conference Call and Webcast Following Lorcaserin FDA Advisory Committee Meeting
6. Arena Pharmaceuticals Submits New Drug Application to FDA for Lorcaserin for Weight Management
7. Published Data Demonstrate Arena Pharmaceuticals Lorcaserin Has Low Abuse Potential
8. Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments
9. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, November 10, 2009
10. Arena Pharmaceuticals Lorcaserin to be Featured in Multiple Presentations at Obesity 2009
11. Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... -- Hutchison China MediTech Limited ("Chi-Med") ... ("HMP"), its drug R&D subsidiary, successfully achieved the ... of fruquintinib in patients with advanced non-squamous non-small ... .  The top-line results demonstrated that the ... endpoint of progression free survival ("PFS"). ...
(Date:9/3/2015)... With a population of more than 1 ... also its single largest potential market for goods and ... all major world economies in the average rate of ... health expenditures. As an in vitro diagnostics (IVD) market, ... United States, western European countries, and Japan. China represents ...
(Date:9/3/2015)... NEW YORK , Sept. 3, 2015 ... successfully used to save millions of lives across globe. ... the Kingdom of Saudi Arabia . ... raw material suppliers, government agencies and regulatory bodies. The ... been studied from two perspectives: by products and by ...
Breaking Medicine Technology:Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 2Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 3IVD in China 2IVD in China 3IVD in China 4IVD in China 5IVD in China 6IVD in China 7IVD in China 8IVD in China 9IVD in China 10IVD in China 11IVD in China 12IVD in China 13Saudi Arabia Defibrillators Market: & Advanced Life Support Defibrillators; End Users; Industry Analysis, Size, Volume, Growth, Trends and Forecast 2014 - 2020 2
... 2 Aerovance Inc. today announced that it ... Drug Administration (FDA) and the U.K. Medicines and ... Phase IIb clinical trial, AeroTrial(TM), of inhaled dry ... begins today in the United States for AeroTrial, ...
... Calif., March 2 Hana,Biosciences (Nasdaq: ... Monitoring,Committee (IDMC) has completed a planned, pre-specified safety ... clinical trial of Marqibo(R) (vincristine,sulfate liposomes injection) for ... second relapse. The results of the IDMC ...
Cached Medicine Technology:Aerovance Initiates Phase IIb Clinical Trial with Aerovant(TM) for the Treatment of Uncontrolled Asthma 2Aerovance Initiates Phase IIb Clinical Trial with Aerovant(TM) for the Treatment of Uncontrolled Asthma 3Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound 2Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound 3Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound 4Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound 5
(Date:9/4/2015)... ... 2015 , ... Mile High Connects today releases “First and Last Mile Connections,” ... sidewalks, bike paths, and other vital supports severely limit access to public transportation for ... dollars to expand public transit, there’s very little support for safe and convenient access ...
(Date:9/4/2015)... ... September 04, 2015 , ... IVF New England, one of the largest and ... Happy Hour" in Manchester for women who wish to learn more about their fertility ... restaurant and lounge, 827 Elm Street, Manchester, NH from 6PM to 7PM , This ...
(Date:9/4/2015)... ... September 04, 2015 , ... Inmar announced today that its ... its Product, Quality and Manufacturers, Dietary Supplements and Supply Chain Committees. , With ... consumer goods industry, it can be difficult for companies to navigate, stay abreast ...
(Date:9/4/2015)... ... September 04, 2015 , ... Keeping mold top of mind ... home is quite common. Mold can grow anywhere - on carpet, clothing, food, paper, ... for excessive moisture and water in the home is key to preventing mold growth, ...
(Date:9/4/2015)... ... 04, 2015 , ... Mike Day, a former Navy SEAL who was shot ... World Championships in Kona on October 10th. , Mike is running the race to ... combat and the cutting-edge treatments that restore their quality of life. More ...
Breaking Medicine News(10 mins):Health News:Missed Connections in Metro Denver Transit 2Health News:IVF New England to Host ManchVegas New Hampshire Fertility Happy Hour on October 15, 2015 in Manchester for Women Who Wish to Learn More About Fertility and Egg Freezing 2Health News:Inmar Experts To Address OTC Manufacturers’ Session on Hazardous Waste and Handling at CHPA Meeting 2Health News:Inmar Experts To Address OTC Manufacturers’ Session on Hazardous Waste and Handling at CHPA Meeting 3Health News:September is Mold Awareness Month 2Health News:September is Mold Awareness Month 3Health News:September is Mold Awareness Month 4Health News:Navy SEAL Shot 27 Times Competes in Ironman World Championship in Kona to Raise Money for Veteran's Suffering from TBI and PTSD 2
... Healthcare ... ... LaVoie Group, a leader in life sciences and pharmaceutical communications, today announced the appointment of ... New York, NY and will lead one of agency,s major pharmaceutical accounts., , , , ...
... cost increased, consumption dropped, study found , FRIDAY, June ... soft drinks may reduce consumption and help lower levels ... new study suggests. , Researchers examined what happened during ... Women,s Hospital in Boston increased the price of regular ...
... ... and outsourcing issues and trends? Submit your questions to Ask Eileen!, a new ... software development outsourcing expert, Eileen Boerger, will personally address questions via email and also ... ...
... Italy, Friday 18 June: Rheumatoid Arthritis (RA) patients face a ... attack) versus the general population, which is comparable to the ... results of a new study presented today at EULAR 2010, ... Rome, Italy. In this Danish, nationwide, 10 year ...
... Chinese Systemic Lupus Erythematosus (SLE) Treatment and Research Group (CSTAR) ... at EULAR 2010, the Annual Congress of the European League ... patients has been scarce to date; but now CSTAR provides ... To date the registry has collated data from 2,104 SLE ...
... of Systemic Lupus Erythematosus (SLE) may differ based on ... a new study presented today at EULAR 2010, the ... Rome, Italy. In particular, the study reinforced differences in ... Results from a Europe-wide study, involving 1,555 SLE ...
Cached Medicine News:Health News:LaVoie Group Adds Carey Pilato As Vice President Based In New York 2Health News:People May Skip Soft Drinks Rather Than Pay More 2Health News:Agilis Solutions Launches Ask Eileen! Online Q&A Column Answers Questions on Cloud, SaaS, Software Development and Outsourcing Issues and Trends 2Health News:Agilis Solutions Launches Ask Eileen! Online Q&A Column Answers Questions on Cloud, SaaS, Software Development and Outsourcing Issues and Trends 3Health News:Risk of heart attack in patients 2Health News:Chinese systemic lupus erythematosus data reveal differences in epidemiology across continents 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: